IRS to Issue Tax Guidance as Schedule III Takes Effect for Medical Cannabis

Federal tax officials will release new guidance for cannabis businesses following the Trump administration's Thursday order moving state-licensed medical marijuana to Schedule III of the Controlled Substances Act.

Acting Attorney General Todd Blanche signed the directive implementing the immediate rescheduling for marijuana products regulated under state medical cannabis programs. The Treasury Department confirmed it's preparing updated tax instructions for affected businesses.

The move marks the first time since 1970 that federal law has recognized a distinction between medical and recreational cannabis. But it also creates a split regulatory framework that industry attorneys say will complicate compliance for multi-state operators.

Tax Relief on the Horizon

The rescheduling effectively ends the application of Section 280E of the tax code for medical cannabis businesses. That provision, which has cost the industry billions in additional tax liability, prohibits companies from deducting ordinary business expenses when trafficking Schedule I or II substances.

Cannabis companies currently pay effective tax rates as high as 70% because they can only deduct cost of goods sold. Schedule III classification allows standard business deductions for expenses like payroll, rent, and marketing—the same treatment given to other industries.

Treasury officials didn't provide a timeline for the new guidance, though tax attorneys expect preliminary instructions within weeks. The IRS will need to clarify how businesses should handle deductions for operations that span both medical and adult-use markets.

Implementation Questions

The order applies only to marijuana "regulated by a state medical cannabis license," creating immediate questions about dual-license operators. Most cannabis companies in states with both medical and recreational programs maintain separate licenses for each market segment.

Industry observers note the administration didn't follow the traditional rulemaking process used during the Biden-era rescheduling effort. That multi-year review included public comment periods and agency coordination. The Trump order bypasses those procedures, raising potential legal challenges.

Several advocacy groups have already questioned whether the Attorney General has unilateral authority to reschedule controlled substances without following Administrative Procedure Act requirements. The Controlled Substances Act gives the AG rescheduling power, but courts have interpreted that authority as requiring formal rulemaking in most cases.

What's Next

Cannabis businesses should prepare for a complex transition period. Companies will need to track which revenue and expenses qualify under the medical license versus recreational operations. State regulatory agencies may need to issue clarifying guidance on what constitutes medical cannabis regulation.

The Treasury Department's forthcoming instructions will likely address how businesses should file amended returns for prior tax years. Some companies may be eligible for refunds if they can demonstrate their operations qualified as medical cannabis businesses under state law.

Meanwhile, recreational cannabis remains Schedule I, maintaining the current tax burden for adult-use operations. That creates a significant competitive advantage for medical-only operators and could reshape business strategies across the industry.

Tax professionals advise cannabis companies to consult with attorneys before making any changes to their filing practices. The IRS guidance will be essential for determining which businesses qualify for the new treatment and how to properly document medical versus recreational operations.

This article is based on original reporting by www.marijuanamoment.net.